diaMentis Joins Dassault Systèmes' Exclusive 3DEXPERIENCE Lab Accelerator
diaMentis, a pioneering company focusing on diagnostic support technologies in mental health, has garnered significant recognition after being selected by Dassault Systèmes for participation in its esteemed 3DEXPERIENCE Lab accelerator program. This selection is particularly noteworthy as it comes from a globally renowned organization, further validating diaMentis' commitment to innovation in the mental health sector.
The 3DEXPERIENCE Lab is designed to support a limited number of innovative startups by providing access to advanced technological resources and expertise crucial for developing solutions to pressing global issues. This partnership will enable diaMentis to leverage the 3DEXPERIENCE platform, facilitating optimization in their industrial processes and enhancing the effectiveness of their groundbreaking technology.
Recently, diaMentis made headlines with the release of their latest results published in the esteemed scientific journal, Biomedical Signal Processing and Control. This publication included findings from the first interim analysis of their patented innovations, showcasing a remarkable ability to identify biological markers associated with bipolar I disorder and schizophrenia. These findings exemplify the high-performance levels attained by diaMentis, emphasizing its impact on the treatment and diagnosis of mental health disorders.
According to Bernard Guimont, Vice President and Chief Financial Officer of diaMentis, this partnership not only marks a significant milestone for the company but also strengthens its mission to enhance clinical outcomes in mental health through technology. He stated, "Being selected by Dassault Systèmes for the 3DEXPERIENCE Lab represents a further recognition from a globally respected organization. This partnership will allow us to optimize our industrial development by leveraging their 3DEXPERIENCE platform and the expertise of their technology and health specialists."
At present, diaMentis is finalizing the development of a Software as a Medical Device (SaMD), which is anticipated to streamline the diagnosis of mental health disorders. Once approved, this device will help clinicians to diagnose conditions such as schizophrenia and bipolar I disorder more efficiently and effectively, utilizing an objective approach that diverges from traditional methods. Normand Tremblay, Co-founder and CEO, highlighted the broader implications of their platform, stating, "We believe our technological platform has the potential to impact not only psychiatric disorders but also non-psychiatric and neurological conditions."
The burden of mental health conditions is immense, imposing substantial economic strain on healthcare systems across the globe. Tremblay emphasizes the importance of the technology developed by diaMentis, asserting that it will not only save lives but also promote efficiency in care delivery.
Founded on research from Laval University, diaMentis maintains a strong portfolio of intellectual property, holding patents in the U.S. and Canada along with pending applications in several countries. The company is actively seeking $10 million in short-term financing to support its clinical validation study across various U.S. and Canadian sites, taking significant steps towards regulatory approval and market entry for its groundbreaking technology. The future appears promising for diaMentis as it positions itself at the forefront of mental health innovation, driven by a commitment to improving diagnostic methodologies and patient outcomes through advanced technology.
The 3DEXPERIENCE Lab is designed to support a limited number of innovative startups by providing access to advanced technological resources and expertise crucial for developing solutions to pressing global issues. This partnership will enable diaMentis to leverage the 3DEXPERIENCE platform, facilitating optimization in their industrial processes and enhancing the effectiveness of their groundbreaking technology.
Recently, diaMentis made headlines with the release of their latest results published in the esteemed scientific journal, Biomedical Signal Processing and Control. This publication included findings from the first interim analysis of their patented innovations, showcasing a remarkable ability to identify biological markers associated with bipolar I disorder and schizophrenia. These findings exemplify the high-performance levels attained by diaMentis, emphasizing its impact on the treatment and diagnosis of mental health disorders.
According to Bernard Guimont, Vice President and Chief Financial Officer of diaMentis, this partnership not only marks a significant milestone for the company but also strengthens its mission to enhance clinical outcomes in mental health through technology. He stated, "Being selected by Dassault Systèmes for the 3DEXPERIENCE Lab represents a further recognition from a globally respected organization. This partnership will allow us to optimize our industrial development by leveraging their 3DEXPERIENCE platform and the expertise of their technology and health specialists."
At present, diaMentis is finalizing the development of a Software as a Medical Device (SaMD), which is anticipated to streamline the diagnosis of mental health disorders. Once approved, this device will help clinicians to diagnose conditions such as schizophrenia and bipolar I disorder more efficiently and effectively, utilizing an objective approach that diverges from traditional methods. Normand Tremblay, Co-founder and CEO, highlighted the broader implications of their platform, stating, "We believe our technological platform has the potential to impact not only psychiatric disorders but also non-psychiatric and neurological conditions."
The burden of mental health conditions is immense, imposing substantial economic strain on healthcare systems across the globe. Tremblay emphasizes the importance of the technology developed by diaMentis, asserting that it will not only save lives but also promote efficiency in care delivery.
Founded on research from Laval University, diaMentis maintains a strong portfolio of intellectual property, holding patents in the U.S. and Canada along with pending applications in several countries. The company is actively seeking $10 million in short-term financing to support its clinical validation study across various U.S. and Canadian sites, taking significant steps towards regulatory approval and market entry for its groundbreaking technology. The future appears promising for diaMentis as it positions itself at the forefront of mental health innovation, driven by a commitment to improving diagnostic methodologies and patient outcomes through advanced technology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.